76 related articles for article (PubMed ID: 32897958)
1. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma.
Ge H; Xiao Y; Qin G; Gu Y; Cai X; Jiang W; Tu X; Yang W; Bi R
Diagn Pathol; 2021 Feb; 16(1):12. PubMed ID: 33541386
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy.
Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI
Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient Ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and PD-L1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
Çakır E; Saygın İ; Ercin ME
Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
[TBL] [Abstract][Full Text] [Related]
7. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
Salem ME; Puccini A; Grothey A; Raghavan D; Goldberg RM; Xiu J; Korn WM; Weinberg BA; Hwang JJ; Shields AF; Marshall JL; Philip PA; Lenz HJ
Mol Cancer Res; 2018 May; 16(5):805-812. PubMed ID: 29523759
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
[TBL] [Abstract][Full Text] [Related]
9. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
Sungu N; Kıran MM
Pol J Pathol; 2023; 74(3):161-170. PubMed ID: 37955535
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel.
Kim SR; Oldfield L; Tone A; Pollett A; Pedersen S; Wellum J; Cesari M; Lajkosz K; Pugh TJ; Ferguson SE
Int J Gynecol Cancer; 2023 Nov; ():. PubMed ID: 37940339
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in ovarian clear cell carcinoma using the 22C3 pharmDx assay.
Gao Y; Pan B; Jia H; Zhang Y; Wang S; Wang Y; Zhang S; Li M; Wang A; Wang X; Zhao K; Zhang Z; Sun J; Guo D; Liang Z
Diagn Pathol; 2024 Jun; 19(1):82. PubMed ID: 38879528
[TBL] [Abstract][Full Text] [Related]
12. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract][Full Text] [Related]
13. MLH1 Loss in Primary Prostate Cancer.
Nourmohammadi Abadchi S; Sena LA; Antonarakis ES; Pritchard CC; Eshleman JR; Konnick EQ; Salipante SJ; Shenderov E; Lotan TL
JCO Precis Oncol; 2023 May; 7():e2200611. PubMed ID: 37196219
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center.
Quaas A; Rehkaemper J; Rueschoff J; Pamuk A; Zander T; Hillmer A; Siemanowski J; Wittig J; Buettner R; Plum P; Popp F; Gebauer F; Bruns CJ; Loeser H; Alakus H; Schoemig-Markiefka B
Front Oncol; 2021; 11():569475. PubMed ID: 34367937
[TBL] [Abstract][Full Text] [Related]
15. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.
Guo J; Tang B; Fu J; Zhu X; Xie W; Wang N; Ding Z; Song Z; Yang Y; Xu G; Xiao X
Cell Oncol (Dordr); 2024 Apr; 47(2):573-585. PubMed ID: 37847338
[TBL] [Abstract][Full Text] [Related]
16. Genetic and immune landscape evolution in MMR-deficient colorectal cancer.
Challoner BR; Woolston A; Lau D; Buzzetti M; Fong C; Barber LJ; Anandappa G; Crux R; Assiotis I; Fenwick K; Begum R; Begum D; Lund T; Sivamanoharan N; Sansano HB; Domingo-Arada M; Tran A; Pandha H; Church D; Eccles B; Ellis R; Falk S; Hill M; Krell D; Murugaesu N; Nolan L; Potter V; Saunders M; Shiu KK; Guettler S; Alexander JL; Lázare-Iglesias H; Kinross J; Murphy J; von Loga K; Cunningham D; Chau I; Starling N; Ruiz-Bañobre J; Dhillon T; Gerlinger M
J Pathol; 2024 Feb; 262(2):226-239. PubMed ID: 37964706
[TBL] [Abstract][Full Text] [Related]
17. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.
Rospo G; Chilà R; Matafora V; Basso V; Lamba S; Bartolini A; Bachi A; Di Nicolantonio F; Mondino A; Germano G; Bardelli A
Genome Med; 2024 Jan; 16(1):15. PubMed ID: 38243308
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.
Yamashita H; Nakayama K; Ishikawa M; Nakamura K; Ishibashi T; Sanuki K; Ono R; Sasamori H; Minamoto T; Iida K; Sultana R; Ishikawa N; Kyo S
Oncotarget; 2018 Jan; 9(5):5652-5664. PubMed ID: 29464025
[TBL] [Abstract][Full Text] [Related]
19. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer.
Gherman A; Bolundut D; Ecea R; Balacescu L; Curcean S; Dina C; Balacescu O; Cainap C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541123
[TBL] [Abstract][Full Text] [Related]
20. Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.
Chung J; Negm L; Bianchi V; Stengs L; Das A; Liu ZA; Sudhaman S; Aronson M; Brunga L; Edwards M; Forster V; Komosa M; Davidson S; Lees J; Tomboc P; Samuel D; Farah R; Bendel A; Knipstein J; Schneider KW; Reschke A; Zelcer S; Zorzi A; McWilliams R; Foulkes WD; Bedgood R; Peterson L; Rhode S; Van Damme A; Scheers I; Gardner S; Robbins G; Vanan MI; Meyn MS; Auer R; Leach B; Burke C; Villani A; Malkin D; Bouffet E; Huang A; Taylor MD; Durno C; Shlien A; Hawkins C; Getz G; Maruvka YE; Tabori U;
J Clin Oncol; 2023 Feb; 41(4):766-777. PubMed ID: 36240479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
